CH627728A5 - Preparation of carboxylic acids derived from indane - Google Patents
Preparation of carboxylic acids derived from indane Download PDFInfo
- Publication number
- CH627728A5 CH627728A5 CH1541077A CH1541077A CH627728A5 CH 627728 A5 CH627728 A5 CH 627728A5 CH 1541077 A CH1541077 A CH 1541077A CH 1541077 A CH1541077 A CH 1541077A CH 627728 A5 CH627728 A5 CH 627728A5
- Authority
- CH
- Switzerland
- Prior art keywords
- indane
- ppm
- protons
- mol
- methyl
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title description 8
- 150000001735 carboxylic acids Chemical class 0.000 title description 3
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 title 2
- XUDCMQBOWOLYCF-UHFFFAOYSA-N 2,3-dihydro-1h-indene-2-carboxylic acid Chemical class C1=CC=C2CC(C(=O)O)CC2=C1 XUDCMQBOWOLYCF-UHFFFAOYSA-N 0.000 description 34
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 34
- -1 thienyl radical Chemical class 0.000 description 32
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 27
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 24
- 125000003118 aryl group Chemical group 0.000 description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 22
- 150000001875 compounds Chemical class 0.000 description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 22
- 239000000203 mixture Substances 0.000 description 20
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 18
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 18
- 238000002329 infrared spectrum Methods 0.000 description 18
- 239000007787 solid Substances 0.000 description 18
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 17
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 17
- 239000000460 chlorine Substances 0.000 description 16
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 16
- 239000000243 solution Substances 0.000 description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 238000001953 recrystallisation Methods 0.000 description 14
- 238000002844 melting Methods 0.000 description 13
- 230000008018 melting Effects 0.000 description 13
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 12
- 238000003756 stirring Methods 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 229910052757 nitrogen Inorganic materials 0.000 description 11
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical group [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 description 10
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 10
- LDUHQKWPUVJJPU-UHFFFAOYSA-N 2,3-dihydro-1h-indene-2-carboxamide Chemical compound C1=CC=C2CC(C(=O)N)CC2=C1 LDUHQKWPUVJJPU-UHFFFAOYSA-N 0.000 description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- 229910052736 halogen Inorganic materials 0.000 description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 8
- 150000002367 halogens Chemical class 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 125000000217 alkyl group Chemical group 0.000 description 7
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 7
- 150000002148 esters Chemical class 0.000 description 7
- 239000000706 filtrate Substances 0.000 description 7
- RMOPJLIMRSAIMD-UHFFFAOYSA-N methyl 2,3-dihydro-1h-indene-2-carboxylate Chemical compound C1=CC=C2CC(C(=O)OC)CC2=C1 RMOPJLIMRSAIMD-UHFFFAOYSA-N 0.000 description 7
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 150000003254 radicals Chemical class 0.000 description 6
- 229910052938 sodium sulfate Inorganic materials 0.000 description 6
- 235000011152 sodium sulphate Nutrition 0.000 description 6
- 125000001424 substituent group Chemical group 0.000 description 6
- 230000007704 transition Effects 0.000 description 6
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 5
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 5
- 229910052801 chlorine Inorganic materials 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 description 4
- 239000005457 ice water Substances 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 206010030113 Oedema Diseases 0.000 description 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 230000000702 anti-platelet effect Effects 0.000 description 3
- 239000003146 anticoagulant agent Substances 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 239000000679 carrageenan Substances 0.000 description 3
- 235000010418 carrageenan Nutrition 0.000 description 3
- 229920001525 carrageenan Polymers 0.000 description 3
- 229940113118 carrageenan Drugs 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 125000001544 thienyl group Chemical group 0.000 description 3
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 3
- MCMQEARTOUMJPK-UHFFFAOYSA-N 2,3-dihydro-1h-indene;propanoic acid Chemical compound CCC(O)=O.C1=CC=C2CCCC2=C1 MCMQEARTOUMJPK-UHFFFAOYSA-N 0.000 description 2
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 2
- RAGSWDIQBBZLLL-UHFFFAOYSA-N 2-chloroethyl(diethyl)azanium;chloride Chemical compound Cl.CCN(CC)CCCl RAGSWDIQBBZLLL-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 2
- 125000002947 alkylene group Chemical group 0.000 description 2
- 125000004103 aminoalkyl group Chemical group 0.000 description 2
- 230000001760 anti-analgesic effect Effects 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 230000005587 bubbling Effects 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 150000007942 carboxylates Chemical class 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 229960003280 cupric chloride Drugs 0.000 description 2
- 125000004663 dialkyl amino group Chemical group 0.000 description 2
- 125000004472 dialkylaminosulfonyl group Chemical group 0.000 description 2
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000155 melt Substances 0.000 description 2
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical compound [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 description 2
- 235000011181 potassium carbonates Nutrition 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- SSOLNOMRVKKSON-UHFFFAOYSA-N proguanil Chemical compound CC(C)\N=C(/N)N=C(N)NC1=CC=C(Cl)C=C1 SSOLNOMRVKKSON-UHFFFAOYSA-N 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- QDLFVXRWLQSBTF-UHFFFAOYSA-N 1,1,2-triethylhydrazine Chemical compound CCNN(CC)CC QDLFVXRWLQSBTF-UHFFFAOYSA-N 0.000 description 1
- KTUOJDXAHZOFCA-UHFFFAOYSA-N 3-(diethylamino)propanamide Chemical class CCN(CC)CCC(N)=O KTUOJDXAHZOFCA-UHFFFAOYSA-N 0.000 description 1
- OEFWPAIUPVVVNE-UHFFFAOYSA-N 5-benzoyl-2,3-dihydro-1h-indene-2-carbonyl chloride Chemical compound C1=C2CC(C(=O)Cl)CC2=CC=C1C(=O)C1=CC=CC=C1 OEFWPAIUPVVVNE-UHFFFAOYSA-N 0.000 description 1
- WOAAHXNXOSCQFP-UHFFFAOYSA-N 5-benzoyl-2,3-dihydro-1h-indene-2-carboxylic acid Chemical compound C1=C2CC(C(=O)O)CC2=CC=C1C(=O)C1=CC=CC=C1 WOAAHXNXOSCQFP-UHFFFAOYSA-N 0.000 description 1
- OVOCLWJUABOAPL-UHFFFAOYSA-N 5-methylfuran-2-carboxylic acid Chemical compound CC1=CC=C(C(O)=O)O1 OVOCLWJUABOAPL-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- BUVKILSTJGGJJN-UHFFFAOYSA-N acetic acid;2,3-dihydro-1h-indene Chemical compound CC(O)=O.C1=CC=C2CCCC2=C1 BUVKILSTJGGJJN-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 150000001266 acyl halides Chemical class 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 230000004931 aggregating effect Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- KIYWWDMHKCPBEI-UHFFFAOYSA-N benzoyl 2,3-dihydro-1H-indene-5-carboxylate Chemical compound C(C1=CC=CC=C1)(=O)OC(=O)C=1C=C2CCCC2=CC=1 KIYWWDMHKCPBEI-UHFFFAOYSA-N 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- DXHPZXWIPWDXHJ-UHFFFAOYSA-N carbon monosulfide Chemical compound [S+]#[C-] DXHPZXWIPWDXHJ-UHFFFAOYSA-N 0.000 description 1
- 150000003857 carboxamides Chemical class 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 150000001879 copper Chemical class 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000012954 diazonium Substances 0.000 description 1
- 150000001989 diazonium salts Chemical class 0.000 description 1
- 238000006193 diazotization reaction Methods 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 239000012259 ether extract Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- DKAGJZJALZXOOV-UHFFFAOYSA-N hydrate;hydrochloride Chemical compound O.Cl DKAGJZJALZXOOV-UHFFFAOYSA-N 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 150000002468 indanes Chemical class 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 231100000926 not very toxic Toxicity 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- HHVIBTZHLRERCL-UHFFFAOYSA-N sulfonyldimethane Chemical group CS(C)(=O)=O HHVIBTZHLRERCL-UHFFFAOYSA-N 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C307/00—Amides of sulfuric acids, i.e. compounds having singly-bound oxygen atoms of sulfate groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C307/02—Monoamides of sulfuric acids or esters thereof, e.g. sulfamic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/28—Halogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/40—Radicals substituted by oxygen atoms
- C07D307/46—Doubly bound oxygen atoms, or two oxygen atoms singly bound to the same carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/22—Radicals substituted by doubly bound hetero atoms, or by two hetero atoms other than halogen singly bound to the same carbon atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Furan Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
Description
627728 627728
REVENDICATIONS 1. Procédé de préparation d'un composé de formule: CLAIMS 1. Process for the preparation of a compound of formula:
dans laquelle R4 est un radical phényle substitué par un ou deux atomes d'halogène, ou un radical thiényle, A est un groupement alkylène inférieur et Q est un groupe alkyle inférieur, caractérisé en ce qu'on prépare un composé de formule: in which R4 is a phenyl radical substituted by one or two halogen atoms, or a thienyl radical, A is a lower alkylene group and Q is a lower alkyl group, characterized in that a compound of formula is prepared:
(I) (I)
cooh dans laquelle R est un radical phényle substitué par au moins un substituant choisi parmi les halogènes et les groupements acétamido, dialkylamino, alkylsulfonyle, dialkylaminosulfonyle et sulfamido; un radical thiényle substitué par au moins un substituant choisi parmi les halogènes et les radicaux alkyle inférieur; ou un radical furyle substitué par un groupe alkyle inférieur, et de ses sels thérapeutique-ment acceptables, caractérisé en ce qu'on fait réagir, selon la réaction de Friedel et Crafts, un composé de formule: cooh in which R is a phenyl radical substituted by at least one substituent chosen from halogens and acetamido, dialkylamino, alkylsulfonyl, dialkylaminosulfonyl and sulfamido groups; a thienyl radical substituted by at least one substituent chosen from halogens and lower alkyl radicals; or a furyl radical substituted by a lower alkyl group, and of its therapeutically acceptable salts, characterized in that a compound of formula is reacted, according to the Friedel and Crafts reaction:
cooh par le procédé selon la revendication 1, on le transforme en son chlorure d'acide, et qu'on fait réagir ce dernier avec une dialkylaminoalkylamine de formule H2N—A—N(Q)2, à une tempé-15 rature comprise entre 10 et 20° C. cooh by the process according to claim 1, it is transformed into its acid chloride, and is reacted with a dialkylaminoalkylamine of formula H2N — A — N (Q) 2, at a temperature between 15 10 and 20 ° C.
20 20
di) di)
COOfi» COOfi »
L'invention a pour objet un procédé de préparation d'un composé de formule: The subject of the invention is a process for the preparation of a compound of formula:
R - R -
dans laquelle R' est un radical alkyle inférieur, avec un halogénure d'acyle de formule: in which R 'is a lower alkyl radical, with an acyl halide of formula:
r-c-x r-c-x
(III) (III)
X étant un atome d'halogène, et qu'on soumet le composé intermédiaire de formule: X being a halogen atom, and submitting the intermediate compound of formula:
(IV) (IV)
coor" coor "
à une hydrolyse alcaline. to alkaline hydrolysis.
2. Procédé de préparation d'un composé de formule: 2. Process for the preparation of a compound of formula:
coor2 coor2
dans laquelle R2 est un radical di(alkyl inférieur)aminoalkyl inférieur et R3 est un radical thiényle ou furyle, caractérisé en ce qu'on prépare un composé de formule: in which R2 is a di (lower alkyl) lower aminoalkyl radical and R3 is a thienyl or furyl radical, characterized in that a compound of formula is prepared:
cooh par le procédé de la revendication 1 et qu'on le condense avec une halogénoalkyldialkylamine correspondante, en milieu solvant alcoolique. cooh by the process of claim 1 and that it is condensed with a corresponding haloalkyldialkylamine, in an alcoholic solvent medium.
3. Procédé de préparation d'un composé de formule: 3. Process for the preparation of a compound of formula:
(I) (I)
cooh cooh
30 dans laquelle R est un radical phényle substitué par au moins un substituant choisi parmi les halogènes et les radicaux acétamido, dialkylamino, alkylsulfonyle, dialkylaminosulfonyle et sulfamido; un radical thiényle substitué par au moins un substituant choisi parmi les halogènes et un radical alkyle inférieur, ou un radical furyle 35 substitué par un radical alkyle inférieur. In which R is a phenyl radical substituted by at least one substituent chosen from halogens and acetamido, dialkylamino, alkylsulfonyl, dialkylaminosulfonyl and sulfamido radicals; a thienyl radical substituted by at least one substituent chosen from halogens and a lower alkyl radical, or a furyl radical substituted by a lower alkyl radical.
En particulier quand R est un radical phényle, il est substitué par au moins un substituant choisi parmi le chlore et les radicaux acétamido, diméthylamino, méthylsulfonyle, diméthylsulfonyle et sulfamido; quand R est un radical thiényle substitué, il est substitué 40 par au moins un substituant choisi parmi le chlore et le radical méthyle; quand R est un radical furyle, il est substitué par un radical méthyle. In particular when R is a phenyl radical, it is substituted by at least one substituent chosen from chlorine and the acetamido, dimethylamino, methylsulfonyl, dimethylsulfonyl and sulfamido radicals; when R is a substituted thienyl radical, it is substituted with at least one substituent chosen from chlorine and the methyl radical; when R is a furyl radical, it is substituted by a methyl radical.
Les nouveaux acides sont notamment les acides p-(diméthyl-amino)benzoyl-5 indane-2 carboxylique, p-(méthylsulfonyl)benzoyl-45 5 indane-2 carboxylique, (parasulfamidobenzoyl)-3 indane-2 carboxylique, (paradiméthylaminosulfonyl)benzoyl-5 indane-2 carboxylique, (acétamido-4' chloro-3') benzoyl-5 indane-2 carboxylique, [(méthyl-3' thénoyl)-2'] -5 indane-2 carboxylique, [(dichloro-4,5' thénoyl)-2/] -5 indane-2 carboxylique, [(méthyl-5' furoyl)-2'] -5 so indane-2 carboxylique. The new acids are in particular p- (dimethyl-amino) benzoyl-5 indane-2 carboxylic acids, p- (methylsulfonyl) benzoyl-45 5 indane-2 carboxylic acid, (parasulfamidobenzoyl) -3 indane-2 carboxylic acid, (paradimethylaminosulfonyl) benzoyl -5 indane-2 carboxylic, (acetamido-4 'chloro-3') benzoyl-5 indane-2 carboxylic, [(methyl-3 'thénoyl) -2'] -5 indan-2 carboxylic, [(dichloro-4, 5 'thenoyl) -2 /] -5 indane-2 carboxylic, [(methyl-5' furoyl) -2 '] -5 so indane-2 carboxylic.
La présente invention a aussi pour objet la préparation des aminoesters, tels les esters dialkyl inférieurs aminoalkyl inférieurs. Ces aminoesters sont dérivés des acides carboxyliques représentés par la formule générale I dans laquelle R est un radical thiényle ou furyle. 55 Les aminoesters sont notamment les (thénoyl-2')-5 indane-2 carboxy-late de N,N-diéthylamino-2' éthyle, (furoyl-2')-5 indane-2 carboxy-late de N,N diéthylamino-2 éthyle. The present invention also relates to the preparation of aminoesters, such as the lower dialkyl lower aminoalkyl esters. These amino esters are derived from the carboxylic acids represented by the general formula I in which R is a thienyl or furyl radical. 55 The aminoesters are in particular the (2-thoyl-2 ') - 5 indane-2 carboxy-late from N, N-diethylamino-2' ethyl, (2-furoyl) - 5-indane-2 carboxy-late from N, N diethylamino -2 ethyl.
La présente invention a aussi pour objet la préparation des amides alkyl inférieurs aminoalkyl inférieurs dérivés des acides 60 carboxyliques, représentés par la formule: The present invention also relates to the preparation of lower alkyl amides lower aminoalkyl derivatives of carboxylic acids, represented by the formula:
conh-a-n(q) conh-a-n (q)
conhan(q) conhan (q)
dans laquelle A est un groupement alkylène inférieur, Q est un groupe alkyle inférieur et R4 est un radical phényle substitué par un in which A is a lower alkylene group, Q is a lower alkyl group and R4 is a phenyl radical substituted by a
3 3
627728 627728
ou deux halogènes, ou un radical thiényle. Les carboxamides sont notamment les diéthylaminoéthylcarboxamides, tels les benzoyl-5 N (N',N'-diéthylamino-2' éthyl)indane-2 carboxamide, (thénoyl-2')-5N (N',N' diéthylamino-2 éthyl)indane-2 carboxamide et (dichloro-2', 5' benzoyl-)5 N (N'N' diéthylamino-2' éthyl)indane-2 carboxamide. s or two halogens, or a thienyl radical. The carboxamides are in particular diethylaminoethylcarboxamides, such as benzoyl-5 N (N ', N'-diethylamino-2' ethyl) indane-2 carboxamide, (thénoyl-2 ') - 5N (N', N 'diethylamino-2 ethyl) indan-2 carboxamide and (dichloro-2 ', 5' benzoyl-) 5 N (N'N 'diethylamino-2' ethyl) indan-2 carboxamide. s
On prépare les nouveaux dérivés à partir d'un ester de formule (II) dans laquelle R' est un groupe alkyle inférieur: The new derivatives are prepared from an ester of formula (II) in which R ′ is a lower alkyl group:
(ii) (ii)
On fait réagir sur ce dernier, selon les conditions de la réaction de 15 Friedel et Crafts, un halogène d'aroyle de formule (II): An aroyl halogen of formula (II) is reacted on the latter, according to the conditions of the Friedel and Crafts reaction.
R4-COX (III) R4-COX (III)
dans laquelle R4 a la signification précédemment citée et X représente un halogène. Ensuite, on soumet le composé obtenu à une 20 hydrolyse alcaline. in which R4 has the abovementioned meaning and X represents a halogen. Then, the compound obtained is subjected to alkaline hydrolysis.
La réaction d'acylation peut être conduite avec ou sans solvant, The acylation reaction can be carried out with or without solvent,
mais de préférence avec un solvant convenable comme le chlorure de méthylène, le sulfure de carbone, etc., à des températures s'échelon-nant de 0° C à la température d'ébullition du solvant, de préférence à 25 la température de reflux du solvant. Parmi les acides de Lewis utilisables, on préfère le chlorure d'aluminium, les différents réactifs pourront être présents en quantités stœchiométriques ou en excès, de préférence en excès en ce qui concerne l'halogénure d'aroyle et le chlorure d'aluminium, cet excès pouvant aller jusqu'à 400%. 30 but preferably with a suitable solvent such as methylene chloride, carbon sulfide, etc., at temperatures ranging from 0 ° C to the boiling point of the solvent, preferably at the reflux temperature solvent. Among the Lewis acids which can be used, aluminum chloride is preferred, the various reagents may be present in stoichiometric amounts or in excess, preferably in excess as regards the aroyl halide and aluminum chloride, this excess of up to 400%. 30
En ce qui concerne en particulier les composés dans lesquels R est un groupe phényle substitué par un radical sulfamido ou diméthyl-sulfamido, on part d'un ester de formule (IV), obtenu par la première étape ci-dessus: As regards in particular the compounds in which R is a phenyl group substituted by a sulfamido or dimethyl-sulfamido radical, one starts from an ester of formula (IV), obtained by the first step above:
r - co ^ (iv) 35 r - co ^ (iv) 35
40 40
coor1 coor1
dans laquelle R' est un groupe alkyle inférieur et R un groupe phényle substitué par un radical amino. wherein R 'is a lower alkyl group and R a phenyl group substituted by an amino radical.
Le composé (IV) dans lequel R et R' ont les significations précédemment citées est soumis à une diazotation selon les techniques connues en soi, puis le sel d'aryldiazonium obtenu est traité par 45 une solution d'anhydride sulfureux dans l'acide acétique en présence d'un sel de cuivre, de préférence le chlorure cuivrique, de façon à obtenir un composé de formule (IV): The compound (IV) in which R and R ′ have the abovementioned meanings is subjected to a diazotization according to the techniques known per se, then the aryldiazonium salt obtained is treated with a solution of sulfur dioxide in acetic acid in the presence of a copper salt, preferably cupric chloride, so as to obtain a compound of formula (IV):
l'eau, en présence d'hydrogène et d'un catalyseur d'hydrogénation, de préférence le palladium sur carbone et à une température appropriée. water, in the presence of hydrogen and a hydrogenation catalyst, preferably palladium on carbon and at an appropriate temperature.
On obtient ainsi les composés de formule (IV) pour lesquels R est un groupe phényle substitué par un radical dimêthylamino, R' ayant la signification précédemment citée. The compounds of formula (IV) are thus obtained for which R is a phenyl group substituted by a dimethylamino radical, R ′ having the meaning cited above.
Enfin, quand R est un radical substitué par au moins un halogène, on obtient ces composés en traitant un composé de formule (IV) dans lequel R est un radical phényle, thiényle ou furyle monosubstitué et R' a la signification précédemment citée, par une solution de l'halogène dans l'acide acétique, cette solution pouvant être saturée ou non, et la réaction ayant lieu à des températures s'échelonnant de la température ambiante à celle du reflux. Finally, when R is a radical substituted by at least one halogen, these compounds are obtained by treating a compound of formula (IV) in which R is a monosubstituted phenyl, thienyl or furyl radical and R 'has the meaning mentioned above, by a solution of halogen in acetic acid, this solution may or may not be saturated, and the reaction taking place at temperatures ranging from room temperature to that of reflux.
L'activité pharmacologique anti-inflammatoire, analgésique et antiagrégeante plaquettaire des composés selon l'invention a été démontrée sur l'animal. The anti-inflammatory, analgesic and anti-platelet aggregation pharmacological activity of the compounds according to the invention has been demonstrated on animals.
A. Les produits sont en général peu toxiques. La DL 50 est déterminée chez la souris. A. The products are generally not very toxic. The LD 50 is determined in mice.
B. L'activité analgésique a été déterminée chez la souris par la méthode de Koster et coll. («Fed. Proc.», 1959,18,412). On cherche la dose active 50 du produit qui, administré per os, diminue de 50% les contractions douloureuses provoquées par l'injection intrapérito-néale d'une solution d'acide acétique. B. The analgesic activity was determined in mice by the method of Koster et al. ("Fed. Proc.", 1959,18,412). We are looking for the active dose 50 of the product which, administered orally, reduces painful contractions caused by intraperitoneal injection of an acetic acid solution by 50%.
C. L'activité anti-inflammatoire a été montrée par le test à l'œdème à la carragénine selon Winter et coll. («Proc. Exp. Biol. Med.», 111, 544-47). On recherche la protection que confère le traitement par le produit administré per os au rat vis-à-vis d'un œdème déclenché par injection sous la voûte plantaire d'une suspension de carragénine. La dose active DA 30 est celle qui inhibe 30% de l'œdème. C. Anti-inflammatory activity was shown by the carrageenan edema test according to Winter et al. ("Proc. Exp. Biol. Med.", 111, 544-47). We seek the protection conferred by treatment with the product administered per os to the rat against edema triggered by injection under the arch of a suspension of carrageenan. The active dose DA 30 is that which inhibits 30% of the edema.
D. L'activité protectrice vis-à-vis de l'inflammation précoce a été déterminée sur le cobaye albinos selon la méthode de Winder et coll. («Arch. Inv. Pharmacodyn.», 1958,116,261). On recherche la DA 50 du produit qui, administré per os à l'animal, diminue de 50% l'érythème produit par l'exposition à un rayonnement ultraviolet de la surface dorsale épilée du cobaye. D. The protective activity against early inflammation was determined on the albino guinea pig according to the method of Winder et al. ("Arch. Inv. Pharmacodyn.", 1958,116,261). We are looking for the DA 50 of the product which, administered orally to the animal, decreases the erythema produced by 50% by exposure to ultraviolet radiation from the shaved dorsal surface of the guinea pig.
E. L'efficacité antiagrégeante plaquettaire est déterminée in vitro par agrégation provoquée au collagène selon la méthode de Börn. E. The antiplatelet efficacy of platelets is determined in vitro by induced aggregation with collagen according to the method of Börn.
Les résultats sont consignés dans le tableau suivant. Les doses actives sont exprimées en mg/kg, à l'exception de l'agrégation plaquettaire où il s'agit de la concentration minimale active en y/ml. The results are recorded in the following table. The active doses are expressed in mg / kg, with the exception of platelet aggregation where it is the minimum active concentration in y / ml.
(Tableau en tête de la page suivante) (Table at the top of the next page)
Les compositions thérapeutiques contenant comme principe actif au moins un composé selon le perfectionnement et un support ou diluant pharmaceutique solide ou liquide peuvent être sous forme de comprimés, de solutions injectables, de suppositoires et analogues. The therapeutic compositions containing as active principle at least one compound according to the improvement and a solid or liquid pharmaceutical carrier or diluent can be in the form of tablets, injectable solutions, suppositories and the like.
r - r -
(IV) 50 (IV) 50
Exemple de formulation Principe actif .... Example of formulation Active ingredient ....
200 mg coor" 200 mg coor "
dans laquelle R' a la même signification que précédemment et R est un radical phényle convenablement substitué par un radical chlorosulfonyle. wherein R 'has the same meaning as above and R is a phenyl radical suitably substituted by a chlorosulfonyl radical.
En traitant ce dernier par l'ammoniac gazeux ou en solution dans l'eau ou dans un alkanol inférieur, on obtient le composé de formule (IV), dans lequel R est un radical phényle substitué par un radical sulfamido. Si on remplace l'ammoniac par la diméthylamine, on obtient un composé de formule (IV) dans lequel R est un radical phényle substitué par un radical diméthylsulfamido. By treating the latter with gaseous ammonia or in solution in water or in a lower alkanol, the compound of formula (IV) is obtained, in which R is a phenyl radical substituted by a sulfamido radical. If the ammonia is replaced by dimethylamine, a compound of formula (IV) is obtained in which R is a phenyl radical substituted by a dimethylsulfamido radical.
En ce qui concerne les composés dans lesquels R est un radical phényle substitué par un radical dimêthylamino, on traite un composé de formule (IV) dans lequel R' est un groupe alkyle inférieur et R un radical phényle substitué par un radical amino, par le formaldéhyde sous sa forme monomère, pur ou en solution dans As regards the compounds in which R is a phenyl radical substituted by a dimethylamino radical, a compound of formula (IV) is treated in which R ′ is a lower alkyl group and R a phenyl radical substituted by an amino radical, by the formaldehyde in its monomeric form, pure or in solution in
Excipients Excipients
Lactose 30 mg Lactose 30 mg
55 Amidon de blé. : 29 mg 55 Wheat starch. : 29 mg
Talc 10 mg Talc 10 mg
Gélatine 5 mg Gelatin 5 mg
Acide alginique 20 mg Alginic acid 20 mg
Fécule 5 mg Starch 5 mg
Stéarate de magnésium 1 mg Magnesium stearate 1 mg
Pour un comprimé de 300 mg For one 300 mg tablet
Les compositions thérapeutiques contenant comme principe actif un dérivé de l'indane selon le perfectionnement sont efficaces en tant 65 qu'anti-inflammatoires, antalgiques et antiagrégeantes plaquettaires à des doses comprises entre 50 et 500 mg par dose unitaire, la posologie pouvant être réglée pour obtenir la réponse thérapeutique optimale. Therapeutic compositions containing as active ingredient an indane derivative according to the improvement are effective as anti-inflammatory, analgesic and anti-platelet aggregating agents at doses of between 50 and 500 mg per unit dose, the dosage can be adjusted for obtain the optimal therapeutic response.
627728 627728
4 4
DL 50 DL 50
Acide acétique DA 50 Acetic acid DA 50
Carragénine DA 30 DA 30 carrageenan
UV DA 50 UV DA 50
Agrégation au collagène Collagen aggregation
Acide [(méthyl-3' thénoyl)-2']-5 indane-2 carboxylique [(3-methyl 'thenoyl) -2'] - 5 indan-2-carboxylic acid
1200 1200
37 37
26 26
25 25
10 10
Acide [(méthyl-5' furoyl)-2']-5 indane-2 carboxylique [(Methyl-5 'furoyl) -2'] - 5 indan-2 carboxylic acid
2400 2400
8 8
10 10
16 16
1 1
Acide [paradiméthylaminobenzoyl]-5 indane-2 carboxylique [Paradimethylaminobenzoyl] -5 indan-2 carboxylic acid
960 960
3 3
14 14
20 20
0,5 0.5
Acide (paraméthylsulfonylbenzoyl)-5 indane-2 carboxylique (Paramethylsulfonylbenzoyl) -5 indane-2 carboxylic acid
2800 2800
35 35
40 40
10 10
1 1
Acide (parasulfamidobenzoyl)-5 indane-2 carboxylique (Parasulfamidobenzoyl) -5 indane-2 carboxylic acid
>3200 > 3200
25 25
43 43
90 90
5 5
Acide (paradiméthylaminosulfonylbenzoyl)-5 indane-2 carboxylique Carboxylic acid (paradimethylaminosulfonylbenzoyl) -5 indane-2
2600 2600
80 80
160 160
>300 > 300
10 10
f(Acétamido-4'chloro-3')benzoyl]-5 indane-2 carboxylate d'éthyle f (Acetamido-4'chloro-3 ') benzoyl] -5 indane-2 ethyl carboxylate
3200 3200
35 35
60 60
80 80
5 5
Acide [(dichloro-4',5' thénoyl)-2]-5 indane-2 carboxylique [(4'-dichloro, 5 'thenoyl) -2] -5 indane-2 carboxylic acid
180 180
30 30
42 42
90 90
7,5 7.5
(Thénoyl-2')-5 indane-2 carboxylate de N,N diéthylamino-2 éthyle, chlorhydrate (2'-Thénoyl ') - 5 indane-2 carboxylate of N, N 2-ethyl-diethylamino, hydrochloride
2160 2160
4 4
8 8
10 10
0,25 0.25
(Furoyl-2')-5 indane-2 carboxylate de N,N diéthylamino-2 éthyle, chlorhydrate (Furoyl-2 ') - 5 indane-2 carboxylate of N, N 2-ethylethylamino, hydrochloride
1200 1200
8 8
18 18
20 20
1 1
Benzoyl-5 N-(N'N' diéthylamino-2' éthyl)indane-2 carboxamide, Oxalate Benzoyl-5 N- (N'N 'diethylamino-2' ethyl) indane-2 carboxamide, Oxalate
1100 1100
30 30
9 9
25 25
2,5 2.5
(Thénoyl-2')-5 N-(N'N' diéthylamino-2' éthyl)indane-2 carboxamide, Oxalate (2-Thénoyl-2) - 5 N- (N'N '2-ethyl diethylamino) 2-indane carboxamide, Oxalate
660 660
2,5 2.5
8 8
10 10
0,25 0.25
(Dichloro-2',5' benzoyl)-5N(N'N' diéthyl-amino-2' éthyl)indane-2 carboxamide, Oxalate (Dichloro-2 ', 5' benzoyl) -5N (N'N 'diethyl-amino-2' ethyl) indan-2 carboxamide, Oxalate
720 720
15 15
25 25
50 50
2,5 2.5
(Diméthylamino-4' benzoyl)-5 indane-2 carboxylate de méthyle (4 'Dimethylamino benzoyl) -5 methyl indane-2 carboxylate
1450 1450
2,5 2.5
12 12
24 24
0,25 0.25
Il est donné ci-après des exemples de préparation des composés qui illustrent le perfectionnement à titre non limitatif. Examples of the preparation of the compounds are given below which illustrate the improvement, without limitation.
Exemple 1 : Example 1:
Acide [(méthyl-3' thénoyl)-2'] -5 indane-2 carboxylique CHo [(3-methyl 'thenoyl) -2'] -5 indan-2 carboxylic acid CHo
Ci6H1403S P.M. = 286,33 Ci6H1403S P.M. = 286.33
a) [ !Méthyl-3' thénoyl)-2'J -5 indane-2 carboxylate de méthyle: C17Hl603S. a) [! Methyl-3 'thenoyl) -2'J -5 indane-2 methyl carboxylate: C17Hl603S.
Dans un réacteur de 250 ml équipé d'une agitation, d'un réfrigérant muni d'une garde à chlorure de calcium, d'une ampoule à In a 250 ml reactor equipped with a stirrer, a condenser fitted with a calcium chloride guard, a vial
brome et d'un thermomètre, on introduit 18,5 g (0,139 mol) de chlorure d'aluminium et 14,1 g (0,08 mol) d'indane-2 carboxylate de 50 méthyle goutte à goutte par l'ampoule à brome. La température atteint 35° C en fin d'addition. On chauffe légèrement pour homogénéiser. Puis, à une température voisine de 20° C, on additionne goutte à goutte 12,8 g (0,08 mol) de chlorure d'acide méthyl-3 thiophène-2 carboxylique. On chauffe ensuite progressivement jusque vers 55 70-80° C. On maintient cette température pendant 30 min, puis laisse revenir vers 40°C. On additionne, à ce moment-là, du chlorure de méthylène puis verse la solution obtenue dans l'eau glacée additionnée d'acide chlorhydrique. La phase organique est décantée, lavée à l'eau sodée puis à l'eau. On sèche sur sulfate de sodium, filtre, 60 concentre le filtrat et distille le résidu. On recueille une fraction huileuse épaisse Ebo,7 torr: 180-200°C. bromine and a thermometer, 18.5 g (0.139 mol) of aluminum chloride and 14.1 g (0.08 mol) of 50 methyl indan-2-carboxylate are introduced dropwise through the ampoule. bromine. The temperature reaches 35 ° C at the end of the addition. Heat slightly to homogenize. Then, at a temperature in the region of 20 ° C., 12.8 g (0.08 mol) of 3-methyl-2-thiophene-2-carboxylic acid chloride are added dropwise. It is then gradually heated up to around 55 70-80 ° C. This temperature is maintained for 30 min, then allowed to return to around 40 ° C. At this point, methylene chloride is added and then the solution obtained is poured into ice water containing hydrochloric acid. The organic phase is decanted, washed with soda water and then with water. It is dried over sodium sulfate, filtered, the filtrate is concentrated and the residue is distilled. A thick oily fraction Ebo is collected, 7 torr: 180-200 ° C.
Spectre infrarouge: Infrared spectrum:
vCO:1740 cm_1vCO:1640 cm-1. vCO: 1740 cm_1vCO: 1640 cm-1.
Spectre RMN: NMR spectrum:
65 — massif de 5 protons aromatiques centré vers 7,4 ppm; 65 - mass of 5 aromatic protons centered around 7.4 ppm;
— pic de 3 protons OCH3 à 3,4 ppm; - peak of 3 OCH3 protons at 3.4 ppm;
— pic de 5 protons indane à 3,33 ppm; - peak of 5 indane protons at 3.33 ppm;
— pic de 3 protons CH3 à 2,4 ppm. - peak of 3 protons CH3 at 2.4 ppm.
5 5
627728 627728
b) Passage à l'acide [-(méthyl-3' thénoyl)-2'] -5 indane-2 carboxylique: b) Transition to [- (methyl-3 'thénoyl) -2'] -5 indane-2 carboxylic acid:
Dans un réacteur de 250 ml équipé d'une agitation et d'un réfrigérant, on introduit successivement 6,7 g (0,0223 mol) d'ester obtenu sous a en solution dans 30 ml de méthanol, 2,8 g (0,05 mol) de s potasse en solution dans 30 cm3 de méthanol. On chauffe à reflux 1 h. On concentre à sec, reprend par l'eau, fait un lavage à l'éther en milieu alcalin. La phase aqueuse est acidifiée à froid par l'acide chlorhydrique; un solide précipite. On l'essore, le lave à l'eau, le sèche. Par recristallisation dans l'acétate d'éthyle, on obtient un io solide fondant à 136-138°C (tube capillaire). 6.7 g (0.0223 mol) of ester obtained under a dissolved in 30 ml of methanol, 2.8 g (0 g) are successively introduced into a 250 ml reactor equipped with stirring and a condenser. 0.05 mol) of potassium hydroxide dissolved in 30 cm3 of methanol. The mixture is heated at reflux for 1 hour. Concentrate to dryness, take up in water, wash with ether in an alkaline medium. The aqueous phase is acidified cold with hydrochloric acid; a solid precipitates. It is wrung, washed with water, dried. By recrystallization from ethyl acetate, a solid io is obtained, melting at 136-138 ° C (capillary tube).
Spectre infrarouge: Infrared spectrum:
vCO: 1700 cm_1vCO:1635 cm"1. vCO: 1700 cm_1vCO: 1635 cm "1.
Spectre RMN: 15 NMR spectrum: 15
— massif de 5 protons aromatiques centré vers 7,32 ppm; - massif of 5 aromatic protons centered around 7.32 ppm;
— pic de 5 protons indane vers 3,4 ppm; - peak of 5 indane protons around 3.4 ppm;
— pic de 3 protons méthyle à 2,47 ppm; - peak of 3 methyl protons at 2.47 ppm;
— pic de 1 proton OH vers 10,7 ppm. - peak of 1 OH proton around 10.7 ppm.
Indice d'acidité: 20 Acidity index: 20
Trouvé: 195. Calculé: 190. Found: 195. Calculated: 190.
Analyse centésimale: Centesimal analysis:
Calculé: C 67,13 H 4,93 S 11,20% Calculated: C 67.13 H 4.93 S 11.20%
Trouvé: C 67,06 H 4,99 S 11,24% 25 Found: C 67.06 H 4.99 S 11.24% 25
Exemple 2: Example 2:
Acide [(méthyl-5' furoyl)-2'] -5 indane-2 carboxylique. [(5-methyl 'furoyl) -2'] -5 indan-2 carboxylic acid.
a) [(Méthyl-5' furoyl)-2'] -5 indane-2 carboxylate de méthyle: a) [(Methyl-5 'furoyl) -2'] -5 methyl indane-2 carboxylate:
CnHl60A. ^ CnHl60A. ^
Dans un réacteur de 250 ml, équipé d'un agitateur, d'un réfrigérant muni d'une garde à chlorure de calcium, d'une ampoule à brome et d'un thermomètre, on introduit 11,4 g (0,086 mol) de chlorure d'aluminium en suspension dans 30 ml de chlorure de méthylène et 5,5 g (0,0382 mol) de chlorure d'acide méthyl-5 furanne carboxylique-2 en solution dans 30 ml de chlorure de méthylène. On amène le mélange à une température de 20° C puis additionne goutte à goutte une solution de 5,6 g (0,0318 mol) d'indane-2 carboxylate de méthyle dans 50 cm3 de chlorure de méthylène. On laisse sous agitation 2 h à température ambiante, puis chauffe 3 h à reflux. On laisse une nuit au repos, puis verse dans un bain d'eau glacée acidulée. On extrait au chlorure de méthylène, lave l'extrait à l'eau sodée, à l'eau, le sèche sur sulfate de sodium, filtre, concentre le filtrat et distille le résidu. On recueille une fraction Ebi ton-: 195-205°C. In a 250 ml reactor, equipped with an agitator, a condenser provided with a calcium chloride guard, a dropping funnel and a thermometer, 11.4 g (0.086 mol) of aluminum chloride suspended in 30 ml of methylene chloride and 5.5 g (0.0382 mol) of chloride of 5-methyl furan carboxylic acid-2 in solution in 30 ml of methylene chloride. The mixture is brought to a temperature of 20 ° C. and then dropwise added a solution of 5.6 g (0.0318 mol) of methyl indan-2 carboxylate in 50 cm3 of methylene chloride. The mixture is left stirring for 2 h at ambient temperature, then heating for 3 h at reflux. It is left to stand overnight, then poured into a bath of acidulated ice water. Extraction is carried out with methylene chloride, the extract is washed with soda water, with water, dried over sodium sulphate, filtered, the filtrate is concentrated and the residue is distilled. An Ebi ton- fraction is collected: 195-205 ° C.
Spectre infrarouge: 55 Infrared spectrum: 55
vCO:1740 cm_1vCO:1645 cm-1. vCO: 1740 cm_1vCO: 1645 cm-1.
Spectre RMN: NMR spectrum:
— massif de 4 protons aromatiques vers 7,33 ppm; - massif of 4 aromatic protons around 7.33 ppm;
— 1 proton aromatique vers 6,2 ppm; - 1 aromatic proton around 6.2 ppm;
— pic de 5 protons indane à 3,3 ppm; - peak of 5 indane protons at 3.3 ppm;
— pic de 3 protons OCH3 à 3,7 ppm; - peak of 3 OCH3 protons at 3.7 ppm;
— pic de 3 protons CH3 à 2,47 ppm. - peak of 3 CH3 protons at 2.47 ppm.
b) Passage à l'acide [(méthyl-5' furoyl)-2'] -5 indane-2 carboxylique: b) Transition to [(methyl-5 'furoyl) -2'] -5 indane-2 carboxylic acid:
Dans un réacteur de 50 ml, on introduit successivement 2,7 g 65 (0,0095 mol) d'ester obtenu sous a en solution dans 16,5 cm3 de méthanol et 1,16 g (0,0208 mol) de potasse en solution dans 16,5 cm3 d'eau. On laisse à température ambiante pendant 48 h. On concentre à sec, reprend par l'eau, fait un lavage à l'éther en milieu alcalin, puis acidifie la phase aqueuse. On extrait à l'éther, sèche sur sulfate de sodium, filtre et concentre le filtrat. Le résidu obtenu après recristallisation dans un mélange acétate d'éthyle/ hexane fond à 128-130°C (tube capillaire). 2.7 g 65 (0.0095 mol) of ester obtained under a dissolved in 16.5 cm3 of methanol and 1.16 g (0.0208 mol) of potassium hydroxide are successively introduced into a 50 ml reactor. solution in 16.5 cm3 of water. The mixture is left at room temperature for 48 h. Concentrate to dryness, take up in water, wash with ether in an alkaline medium, then acidify the aqueous phase. Extracted with ether, dried over sodium sulfate, filtered and concentrated the filtrate. The residue obtained after recrystallization from an ethyl acetate / hexane mixture melts at 128-130 ° C (capillary tube).
Spectre infrarouge: Infrared spectrum:
vCOnOOcm-SCOilôSS cm"1. vCOnOOcm-SCOilôSS cm "1.
Spectre RMN: NMR spectrum:
— 1 proton OH vers 10,6 ppm; - 1 OH proton around 10.6 ppm;
— massif de 4 protons aromatiques centré vers 7,5 ppm; - massif of 4 aromatic protons centered around 7.5 ppm;
— 1 proton aromatique vers 6,8 ppm; - 1 aromatic proton around 6.8 ppm;
— 5 protons indane à 3,36 ppm; - 5 indane protons at 3.36 ppm;
— 3 protons CH3 à 2,47 ppm. - 3 protons CH3 at 2.47 ppm.
Analyse centésimale: Centesimal analysis:
Calculé: C 71,10 H 5,22% Calculated: C 71.10 H 5.22%
Trouvé: C 70,99 H 5,16% Found: C 70.99 H 5.16%
Exemple 3: Example 3:
Acide (dimêthylamino-4' benzoyl)-5 indane-2 carboxylique. (4-Dimethylamino-benzoyl) -5 indane-2 carboxylic acid.
a) (Diméthylamino-4' benzoyl) -5 indane-2 carboxylate de méthyle: a) (4-dimethylamino benzoyl) -5 methyl indane-2 carboxylate:
C20H21NO3. C20H21NO3.
On peut procéder ainsi: We can proceed as follows:
a) Dans un autoclave de 250 cm3, on introduit 5 g (0,017 mol) d'(amino-4' benzoyl)-5 indane-2 carboxylate de méthyle, 100 cm3 d'éthanol, 26 cm3 d'aldéhyde formique à 36% dans l'eau, en présence de 2 g de Pd/C à 5%. On chauffe à environ 40°C avec agitation après avoir chargé l'autoclave avec de l'hydrogène. Après absorption de la quantité théorique, on filtre pour éliminer le catalyseur. On concentre l'éthanol sous vide, reprend par de l'eau et extrait à l'éther. On sèche sur sulfate de sodium, filtre et concentre le filtrat. Le résidu après recristallisation dans un mélange acétate d'éthyle/diisopropyléther fond à 87-89° C (tube capillaire). a) In a 250 cm3 autoclave, 5 g (0.017 mol) of (amino-4 'benzoyl) -5 methyl indane-2 carboxylate, 100 cm3 of ethanol, 26 cm3 of 36% formaldehyde are introduced. in water, in the presence of 2 g of Pd / C at 5%. The mixture is heated to approximately 40 ° C. with stirring after having loaded the autoclave with hydrogen. After absorption of the theoretical amount, it is filtered to remove the catalyst. The ethanol is concentrated in vacuo, taken up in water and extracted with ether. It is dried over sodium sulfate, filtered and the filtrate is concentrated. The residue after recrystallization from an ethyl acetate / diisopropyl ether mixture melts at 87-89 ° C (capillary tube).
Spectre infrarouge: Infrared spectrum:
vCO:1740 cm"1 vCO: 1640 cm-1. vCO: 1740 cm "1 vCO: 1640 cm-1.
Disparition des bandes NH2. Disappearance of NH2 bands.
Spectre RMN: NMR spectrum:
— doublet de 2 protons aromatiques: 7,85 ppm; - doublet of 2 aromatic protons: 7.85 ppm;
— multiplet de 2 protons aromatiques: 7,55 ppm; - multiplet of 2 aromatic protons: 7.55 ppm;
— multiplet de 1 proton aromatique: 7,25 ppm; - multiplet of 1 aromatic proton: 7.25 ppm;
— doublet de 2 protons aromatiques: 6,7 ppm; - doublet of 2 aromatic protons: 6.7 ppm;
— pic de 3 protons CH3: 3,8 ppm; - peak of 3 CH3 protons: 3.8 ppm;
— massif de 5 protons indane: 3,35 ppm; - solid mass of 5 indane protons: 3.35 ppm;
— pic de 6 protons CH3 : 3,1 ppm. - peak of 6 CH3 protons: 3.1 ppm.
Analyse centésimale: Centesimal analysis:
Calculé: C 74,29 H 6,55 N4,33% Calculated: C 74.29 H 6.55 N4.33%
Trouvé: C 74,41 H 6,60 N4,42% Found: C 74.41 H 6.60 N 4.42%
b) Dans un autoclave de 125 cm3, on introduit 9,6 g (0,068 mol) d'iodure de méthyle, 4,9 g (0,034 mol + 5%) de K2C03, 30 cm3 de diméthylformamide et 5 g (0,017 mol) d'(amino-4' benzoyl)-5 indane-2 carboxylate de méthyle. On laisse sous agitation 24 h. On évapore le diméthylformamide sous vide, reprend par de l'eau, extrait à l'éther. On sèche sur sulfate, filtre et concentre le filtrat. Le résidu obtenu est recristallisé dans un mélange acétate d'éthylediisopropyl-éther. On obtient un produit dont les caractéristiques physiques et spectrales sont identiques à celles du produit obtenu selon a. b) 9.6 g (0.068 mol) of methyl iodide, 4.9 g (0.034 mol + 5%) of K2CO3, 30 cm3 of dimethylformamide and 5 g (0.017 mol) are introduced into a 125 cm3 autoclave of methyl (4-amino benzoyl) -5 indan-2 carboxylate. The mixture is left stirring for 24 h. The dimethylformamide is evaporated in vacuo, taken up in water, extracted with ether. It is dried over sulfate, filtered and the filtrate is concentrated. The residue obtained is recrystallized from an ethylediisopropyl ether acetate mixture. A product is obtained whose physical and spectral characteristics are identical to those of the product obtained according to a.
627728 627728
c) Passage à l'acide (dimèthylamino-4' benzoyl)-5 indane-2 carboxylique: c) Transition to (dimethylamino-4 'benzoyl) -5 indane-2 carboxylic acid:
Selon l'exemple lb, à partir de 5,6 g (0,017 mol) de (diméthyl-amino-4' benzoyl)-5 indane carboxylate de méthyle et 1,95 g (0,0348 mol) de potasse dans 60 ml de méthanol. Par recristallisation dans l'acétate d'éthyle, on obtient un solide fondant à 164-165°C (tube capillaire). According to Example 1b, from 5.6 g (0.017 mol) of (dimethyl-amino-4 'benzoyl) -5 indane methyl carboxylate and 1.95 g (0.0348 mol) of potassium hydroxide in 60 ml of methanol. By recrystallization from ethyl acetate, a solid melting at 164-165 ° C. is obtained (capillary tube).
Spectre infrarouge: Infrared spectrum:
vCO:173ö cm-1 vCO:1620 cm-1. vCO: 173ö cm-1 vCO: 1620 cm-1.
Spectre RMN: NMR spectrum:
— massif de 7 protons aromatiques centré vers 7,23 ppm; - massif of 7 aromatic protons centered around 7.23 ppm;
— pic de 5 protons indane à 3,3 ppm; - peak of 5 indane protons at 3.3 ppm;
— pic de 6 protons CH3 à 3,1 ppm. - peak of 6 protons CH3 at 3.1 ppm.
a) Selon l'exemple 1 a, on prépare le (paraniéthylsulfonyl) benzoyl-5 indanecarboxylate de méthyle à partir de 14,5 g a) According to Example 1 a, methyl (paraniethylsulfonyl) benzoyl-5 indanecarboxylate is prepared from 14.5 g
(0,107 mol) de chlorure d'aluminium et 11 g (0,0475 mol) de chlorure d'acide paraméthylsulfonylbenzoïque, le tout dans 60 ml de chlorure s de méthylène, et 7 g (0,0397 mol) d'indane-2 carboxylate de méthyle dans 30 ml de chlorure de méthylène. Après concentration et reprise du résidu par l'hexane, on obtient un solide que l'on utilise brut. (0.107 mol) of aluminum chloride and 11 g (0.0475 mol) of paramethylsulfonylbenzoic acid chloride, all in 60 ml of methylene chloride, and 7 g (0.0397 mol) of indan-2 methyl carboxylate in 30 ml of methylene chloride. After concentration and recovery of the residue with hexane, a solid is obtained which is used crude.
b) Selon l'exemple 1 b, on prépare l'acide à partir de 3 g (0,0084 mol) d'ester obtenu sous a, 1,1 g (0,02 mol) de potasse dans 50 ml de méthanol. Par recristallisation dans l'éthanol, on obtient un solide fondant à 187-190°C (tube capillaire). b) According to Example 1b, the acid is prepared from 3 g (0.0084 mol) of ester obtained under a, 1.1 g (0.02 mol) of potassium hydroxide in 50 ml of methanol. By recrystallization from ethanol, a solid melting at 187-190 ° C is obtained (capillary tube).
Analyse centésimale: Centesimal analysis:
Calculé: C 73,77 H 6,19 N4,53% Calculated: C 73.77 H 6.19 N 4.53%
Trouvé: C 73,90 H 6,05 N4,53% Found: C 73.90 H 6.05 N 4.53%
Exemple 4: Example 4:
Acide (paraméthylsulfonyl) benzoyl-5 indane-2 carboxylique. (Paramethylsulfonyl) benzoyl-5 indane-2 carboxylic acid.
ch3-s02 ch3-s02
c18h16o5s c18h16o5s
P.M. = 344,37 M.P. = 344.37
Spectre infrarouge: Infrared spectrum:
vCO:1710 cm-1vCO:1670 cm"1. vCO: 1710 cm-1vCO: 1670 cm "1.
15 Spectre RMN: 15 NMR spectrum:
— massif de 7 protons aromatiques centré vers 7,8 ppm; - massif of 7 aromatic protons centered around 7.8 ppm;
— pic de 5 protons indane à 3,33 ppm; - peak of 5 indane protons at 3.33 ppm;
— pic de 3 protons CH3 à 3,17 ppm. - peak of 3 CH3 protons at 3.17 ppm.
20 Indice d'acidité: 20 Acidity index:
Calculé: 163. Trouvé: 155. Calculated: 163. Found: 155.
Analyse centésimale: Centesimal analysis:
Calculé: C 62,78 H 4,68 S 9,31% 25 Trouvé: C 62,90 H 5,01 S 9,17% Calculated: C 62.78 H 4.68 S 9.31% 25 Found: C 62.90 H 5.01 S 9.17%
Exemple 5: Example 5:
. 30 Acide (parasulfamidobenzoyl)-S indane-2 carboxylique. . 30 (Parasulfamidobenzoyl) -S indan-2 carboxylic acid.
h2n - s02. h2n - s02.
C17H15N05S P.M. = 345,36 C17H15N05S P.M. = 345.36
a) (ParachlorosulfonylbenzoylJ-5 indane-2 carboxylate de méthyle: 40 C1BHlsClOsS a) (ParachlorosulfonylbenzoylJ-5 indane-2 methyl carboxylate: 40 C1BHlsClOsS
Dans un réacteur de 250 ml avec agitation, thermomètre et ampoule à brome, on introduit 14,7 g (0,05 mol) d'(amino-4' 14.7 g (0.05 mol) of (4-amino) are introduced into a 250 ml reactor with stirring, thermometer and dropping funnel
benzoyl)-5 indane-2 carboxylate de méthyle. A température comprise entre 0 et 10° C, on additionne 40 ml d'acide chlorhydrique à 24% 45 puis, entre 0 et 5"JC, une solution de 3,8 g de nitrite de sodium dans 10 ml d'eau. Le sel de diazonium ainsi formé est ajouté ensuite vers benzoyl) -5 methyl indane-2 carboxylate. At a temperature between 0 and 10 ° C., 40 ml of 24% hydrochloric acid 45 are added, then, between 0 and 5 "JC, a solution of 3.8 g of sodium nitrite in 10 ml of water. diazonium salt thus formed is then added to
cooh cooh
15°C à un mélange agité de 80 ml d'acide acétique saturé d'anhydride sulfureux et 2,8 g de chlorure cuivrique dissous dans 5 ml d'eau. On laisse revenir à température ambiante, tiédit vers 40° C pour finir la réaction, laisse au repos une nuit. Le lendemain, on reprend par l'eau glacée, essore le solide qui précipite. On s'assure du produit obtenu par spectrographie RMN et infrarouge. 15 ° C to a stirred mixture of 80 ml of acetic acid saturated with sulfur dioxide and 2.8 g of cupric chloride dissolved in 5 ml of water. The mixture is left to return to ambient temperature, warmed to around 40 ° C. to finish the reaction, left to stand overnight. The next day, we take up in ice water, wring out the solid which precipitates. We make sure of the product obtained by NMR and infrared spectrography.
b) Passage au (parasulfamidobenzoyl)-5 indane-2 carboxylate de méthyle: b) Transition to methyl (parasulfamidobenzoyl) -5 indane-2 carboxylate:
h2n - s02 h2n - s02
c18h17no5s c18h17no5s
P.M. = 359,40 M.P. = 359.40
Dans un réacteur de 500 ml avec agitation, réfrigérant, ampoule à brome, on introduit 15,6 g (0,041 mol) du dérivé obtenu sous a, 150 ml de chloroforme. Puis, avec une bonne agitation, on additionne 100 ml d'ammoniaque à 15%. On laisse agiter l'A h à température ambiante. On reprend par l'eau et le chloroforme. La phase chloroformique est décantée, séchée sur sulfate de sodium, filtrée et concentrée. Par recristallisation du résidu dans un mélange acétate d'éthyle/éther diisopropylique, on obtient un solide fondant à 147-149°C (tube capillaire). 15.6 g (0.041 mol) of the derivative obtained under a, 150 ml of chloroform are introduced into a 500 ml reactor with stirring, condenser, dropping funnel. Then, with good stirring, 100 ml of 15% ammonia are added. The A h is allowed to stir at room temperature. It is taken up in water and chloroform. The chloroform phase is decanted, dried over sodium sulfate, filtered and concentrated. By recrystallization of the residue in an ethyl acetate / diisopropyl ether mixture, a solid melting is obtained at 147-149 ° C (capillary tube).
Spectre infrarouge: Infrared spectrum:
vNH:3400-3320 cm"NCO:1745 cm"1 vCO:1660 cm-1. vNH: 3400-3320 cm "NCO: 1745 cm" 1 vCO: 1660 cm-1.
CO CO
cooch cooch
3 3
Spectre RMN: NMR spectrum:
— massif de 7 protons aromatiques vers 7,66 ppm; - range of 7 aromatic protons around 7.66 ppm;
— pic de 2 protons NH2 à 6,1 ppm; - peak of 2 NH2 protons at 6.1 ppm;
— pic de 3 protons OCH3 à 3,7 ppm; - peak of 3 OCH3 protons at 3.7 ppm;
— pic de 5 protons indane à 3,3 ppm. - peak of 5 indane protons at 3.3 ppm.
c) Passage à l'acide: c) Transition to acid:
En opérant selon l'exemple 1 b à partir de 11 g (0,0306 mol) 65 d'ester obtenu sous b en solution dans 100 ml d'éthanol et 3,4 g (0,06 mol) de potasse en solution dans 100 ml d'eau, on obtient, après recristallisation du produit obtenu dans un mélange acide acétique/eau, un solide fondant à 157-158°C (tube capillaire). By operating according to Example 1 b from 11 g (0.0306 mol) 65 of ester obtained under b in solution in 100 ml of ethanol and 3.4 g (0.06 mol) of potassium hydroxide in solution in 100 ml of water, after recrystallization of the product obtained from an acetic acid / water mixture, a solid melting at 157-158 ° C. is obtained (capillary tube).
7 7
627728 627728
Spectre infrarouge: Infrared spectrum:
vNH:3320 cm"1 vCO: 1720 cm"1 vCO: 1650 cm-1. vNH: 3320 cm "1 vCO: 1720 cm" 1 vCO: 1650 cm-1.
Spectre RMN: NMR spectrum:
— massif de 7 protons aromatiques vers 7,6 ppm; - range of 7 aromatic protons around 7.6 ppm;
— pic de 2 protons NH2 vers 6,6 ppm; - peak of 2 NH2 protons around 6.6 ppm;
— 1 proton OH vers 10,5 ppm; - 1 OH proton at around 10.5 ppm;
— 5 protons indane à 3,4 ppm. - 5 indane protons at 3.4 ppm.
Analyse centésimale: Centesimal analysis:
Calculé: C 59,12 H 4,38 N4,06 S 9,28% Trouvé: C 59,38 H 4,14 N4,09 S 9,24% Calculated: C 59.12 H 4.38 N 4.06 S 9.28% Found: C 59.38 H 4.14 N 4.09 S 9.24%
Exemple 6: Example 6:
Acide (paradiméthylaminosulfonyl) benzoyl-5 indane-2 carboxylique: (Paradimethylaminosulfonyl) benzoyl-5 indane-2 carboxylic acid:
ch ch
3\ 3 \
n-so, n-so,
ch ch
3 3
c19h19no5s c19h19no5s
P.M. = 373,41 M.P. = 373.41
a) (Paradiméthylaminosulfonyl) benzoyl-5 indane-2 carboxylate de méthyle: CZ0H21NOsS: a) (Paradimethylaminosulfonyl) benzoyl-5 indane-2 methyl carboxylate: CZ0H21NOsS:
On le prépare selon l'exemple 5 b à partir de 28 g (0,074 mol) de (parachlorosulfonylbenzoyl)-5 indane-2 carboxylate de méthyle dans 90 cm3 de chloroforme, 34 ml (0,148 mol) d'une solution de diméthylamine à 40% dans l'eau. It is prepared according to Example 5b from 28 g (0.074 mol) of methyl (parachlorosulfonylbenzoyl) -5 indane-2 carboxylate in 90 cm3 of chloroform, 34 ml (0.148 mol) of a 40-dimethylamine solution % in water.
b) Passage à l'acide: b) Transition to acid:
Selon l'exemple 5 c, à partir de 21 g (0,0545 mol) d'ester brut obtenu à a dans 200 ml d'eau, 6,15 g (0,11 mol) de potasse dans 200 ml d'éthanol. Après recristallisation dans un mélange acétate d'éthyl/hexane, on obtient un solide fondant à 144-145°C (tube capillaire). According to Example 5c, from 21 g (0.0545 mol) of crude ester obtained at a in 200 ml of water, 6.15 g (0.11 mol) of potassium hydroxide in 200 ml of ethanol . After recrystallization from an ethyl acetate / hexane mixture, a solid melting at 144-145 ° C. is obtained (capillary tube).
Spectre infrarouge: Infrared spectrum:
vCO:1700 cm ~1 mCO : 1660 cm ~1. vCO: 1700 cm ~ 1 mCO: 1660 cm ~ 1.
cooh cooh
Spectre RMN: NMR spectrum:
■— pic de 4 protons aromatiques à 7,97 ppm; ■ - peak of 4 aromatic protons at 7.97 ppm;
— massif de 3 protons aromatiques à 7,53 ppm; - massif of 3 aromatic protons at 7.53 ppm;
— pic de 5 protons indane à 3,3 ppm; - peak of 5 indane protons at 3.3 ppm;
— pic de 6 protons CH3 à 2,8 ppm. - peak of 6 CH3 protons at 2.8 ppm.
Analyse centésimale: Centesimal analysis:
Calculé: Trouvé: Calculated: Found:
C 61,11 C 61,09 C 61.11 C 61.09
H 5,13 H 5,19 H 5.13 H 5.19
N 3,75 N 3,71 N 3.75 N 3.71
S 8,57% S 8,64% S 8.57% S 8.64%
Exemple 7: Example 7:
35 [(Acétamido-4' chloro-3') benzoyl] -5 indane-2 carboxylate d'éthyle: 35 [(Acetamido-4 'chloro-3') benzoyl] -5 indane-2 ethyl carboxylate:
ch3-co-nh c21h20cino4 ch3-co-nh c21h20cino4
P.M. = 385,8 M.P. = 385.8
co. co.
cooc2h5 cooc2h5
Dans un réacteur de 250 ml avec agitation, réfrigérant, ampoule à • brome et thermomètre, on introduit 8,8 g (0,025 mol) de (para-acétamidobenzoyl)-5 indane-2 carboxylate d'éthyle, 30 ml d'acide acétique. A une température voisine de 10°C, on rajoute goutte à goutte 40 ml d'acide acétique saturé de chlore. La suspension initiale disparaît progressivement. On laisse revenir 1 h à température ambiante, puis concentre l'acide acétique sous vide. On obtient une huile qui, par recristallisation dans un mélange acétate d'éthyle/ hexane, donne un solide fondant à 126-127°C (tube capillaire). 8.8 g (0.025 mol) of ethyl (para-acetamidobenzoyl) -5 indane-2 carboxylate, 30 ml of acetic acid are introduced into a 250 ml reactor with stirring, condenser, • dropping funnel and thermometer. . At a temperature in the region of 10 ° C., 40 ml of acetic acid saturated with chlorine are added dropwise. The initial suspension gradually disappears. The mixture is left to return to ambient temperature for 1 hour, then the acetic acid is concentrated under vacuum. An oil is obtained which, by recrystallization from an ethyl acetate / hexane mixture, gives a solid, melting at 126-127 ° C (capillary tube).
Spectre infrarouge: Infrared spectrum:
vNH:3350 cm"1 vCO:1740 cm"1 vCO:1690 cm "SCO: 1650 cm"1. vNH: 3350 cm "1 vCO: 1740 cm" 1 vCO: 1690 cm "SCO: 1650 cm" 1.
Spectre RMN: NMR spectrum:
— 1 proton aromatique vers 8,6 ppm; - 1 aromatic proton around 8.6 ppm;
— massif de 6 protons aromatiques centré vers 7,5 ppm; - range of 6 aromatic protons centered around 7.5 ppm;
— quadruplet de 2 protons CH2 vers 4,2 ppm; - quadruplet of 2 CH2 protons around 4.2 ppm;
— 5 protons indane à 3,33 ppm; - 5 indane protons at 3.33 ppm;
— pic de 3 protons CH3 à 2,23 ppm; - peak of 3 CH3 protons at 2.23 ppm;
— pic de 3 protons CH3 à 1,3 ppm. - peak of 3 CH3 protons at 1.3 ppm.
Analyse centésimale: Centesimal analysis:
Calculé: C 65,37 H 5,23 Cl 9,19 N3,63% Trouvé: C 65,50 H 5,22 Cl 9,15 N3,63% Calculated: C 65.37 H 5.23 Cl 9.19 N3.63% Found: C 65.50 H 5.22 Cl 9.15 N3.63%
Exemple 8: Example 8:
Acide [(dichloro-4', 5' thénoyl)-2'J -5 indane-2 carboxylique: Acid [(dichloro-4 ', 5' thenoyl) -2'J -5 indane-2 carboxylic:
627728 627728
Dans un réacteur de 250 ml équipé d'une agitation, d'un réfrigérant, d'une ampoule à brome et d'un tube permettant un barbotage gazeux au sein du mélange réactionnel, on introduit 5,2 g (0,017 mol) d'acide [(chloro-5' thénoyl)-2']-5 indane-2 carboxylique. On y ajoute vers 15°C 27 ml d'acide acétique saturé de chlore. On chauffe ensuite au bain-marie vers 75°C tout en faisant barboter du chlore au sein du mélange réactionnel. Après refroidissement, on isole un solide par essorage. Ce dernier, recristallisé dans l'acétate d'éthyle, voit son point de fusion se stabiliser à 190-192°C (tube capillaire). 5.2 g (0.017 mol) of is introduced into a 250 ml reactor equipped with stirring, a condenser, a dropping funnel and a tube allowing a gas bubbling within the reaction mixture. [(chloro-5 'thénoyl) -2'] - 5 indane-2 carboxylic acid. 27 ml of acetic acid saturated with chlorine are added thereto at around 15 ° C. Then heated in a water bath to 75 ° C while bubbling chlorine into the reaction mixture. After cooling, a solid is isolated by wringing. The latter, recrystallized from ethyl acetate, sees its melting point stabilize at 190-192 ° C (capillary tube).
Spectre infrarouge: Infrared spectrum:
vCO:1720 cm" SCO: 1650 cm"1. vCO: 1720 cm "SCO: 1650 cm" 1.
Spectre RMN: NMR spectrum:
— massif de 3 protons indane plus 1 proton thiophène centré vers 7,5 ppm; - mass of 3 indane protons plus 1 thiophene proton centered around 7.5 ppm;
— pic de 5 protons indane à 3,33 ppm. - peak of 5 indane protons at 3.33 ppm.
Analyse centésimale: Centesimal analysis:
Calculé: C 52,80 H 2,95 Cl 20,78 S 9,40% Calculated: C 52.80 H 2.95 Cl 20.78 S 9.40%
Trouvé: C 52,86 H 2,98 Cl 20,82 S 9,48% Found: C 52.86 H 2.98 Cl 20.82 S 9.48%
Exemple 9: Example 9:
(Thénoyl-2')-5 indane-2 carboxylate de N,N diéthylamino-2' éthyle: (2'-Thénoyl ') - 2 indane-2, N, N-2' diethylamino carboxylate ethyl:
C21H25N03S P.M. = 371,48 C21H25N03S P.M. = 371.48
a) Dans un réacteur de 500 ml équipé d'une agitation, d'un réfrigérant, d'une ampoule à brome, on introduit successivement 27,1 g (0,1 mol) d'acide (thénoyl-2')-5 indane-2 carboxylique, 200 ml d'isopropanol, 16,6 g (0,1 mol + 20%) de carbonate de potassium, 17,2 g (0,1 mol) de chlorhydrate de chloroéthyldiéthylamine, 150 ml d'isopropanol. On chauffe 15 h à reflux. On concentre à sec, reprend par l'eau et l'acide chlorhydrique dilué, fait un lavage à l'éther en milieu acide. On passe en milieu alcalin sur la phase aqueuse et extrait à l'éther. On sèche sur sulfate de sodium, filtre et concentre le filtrat. On distille le résidu et recueille une fraction Eb0 7_0 8 toir 230-240°C. a) In a 500 ml reactor equipped with stirring, a condenser, a dropping funnel, 27.1 g (0.1 mol) of (2-thénl-2 ') acid are successively introduced. indan-2 carboxylic, 200 ml of isopropanol, 16.6 g (0.1 mol + 20%) of potassium carbonate, 17.2 g (0.1 mol) of chloroethyldiethylamine hydrochloride, 150 ml of isopropanol. It is heated for 15 h at reflux. Concentrate to dryness, take up in water and dilute hydrochloric acid, wash with ether in an acid medium. One passes in an alkaline medium on the aqueous phase and extracted with ether. It is dried over sodium sulfate, filtered and the filtrate is concentrated. The residue is distilled and a fraction Eb0 7_0 8 roof 230-240 ° C is collected.
Spectre infrarouge: Infrared spectrum:
vCO:1740 cm-1 vCO:1650 cm-1. vCO: 1740 cm-1 vCO: 1650 cm-1.
Spectre RMN: NMR spectrum:
— massif de 6 protons aromatiques vers 7,47 ppm; - range of 6 aromatic protons around 7.47 ppm;
— triplet de 2 protons CH2 vers 4,2 ppm; - triplet of 2 CH2 protons around 4.2 ppm;
— pic de 5 protons indane à 3,33 ppm; - peak of 5 indane protons at 3.33 ppm;
35 35
— massif de 6 protons CH2 vers 2,7 ppm; - mass of 6 CH2 protons around 2.7 ppm;
— triplet de 6 protons CH3 vers 1,07 ppm. - triplet of 6 CH3 protons around 1.07 ppm.
b) Passage au chlorhydrate: b) Switching to the hydrochloride:
C21H26C1N03S. P.M. = 407,94. C21H26C1N03S. M.P. = 407.94.
Selon les techniques connues, on obtient, après recristallisation dans l'éthanol, un solide fondant à 157-158°C (tube capillaire). According to known techniques, after recrystallization from ethanol, a solid melting at 157-158 ° C. is obtained (capillary tube).
Indice d'acidité: Acidity index:
Trouvé: 132. Calculé: 137. Found: 132. Calculated: 137.
Spectre infrarouge: Infrared spectrum:
vCO:1745 cm_1vCO:1630 cm-1. vCO: 1745 cm_1vCO: 1630 cm-1.
Analyse centésimale (chlorhydrate) : Centesimal analysis (hydrochloride):
Calculé: C 61,83 H 6,43 Cl 8,69 N3,43 S 7,86% Calculated: C 61.83 H 6.43 Cl 8.69 N3.43 S 7.86%
Trouvé: C 61,86 H 6,57 Cl 8,56 N3,40 S 7,89% Found: C 61.86 H 6.57 Cl 8.56 N3.40 S 7.89%
Exemple 10: Example 10:
(Furoyl-2') -5 indane-2 carboxylate de N,N diéthylamino-2' éthyle: (Furoyl-2 ') -5 indane-2 carboxylate of N, N 2-ethylethylamino:
C2iH25N04 P.M. = 355,42 C2iH25N04 P.M. = 355.42
cooch2-ch2-n cooch2-ch2-n
c2h5 c2h5
C2H5 C2H5
Préparé selon l'exemple 9 à partir de 21,4 g (0,0835 mol) d'acide (furoyl-2')-5 indane-2 carboxylique, 14,2 g (0,0835 mol 4- 20%) de carbonate de potassium et 14,4 g (0,0835 mol) de chlorhydrate de chloroéthyldiéthylamine. Par distillation, on recueille une fraction Ebo,5-0,4 torr* 200-220°C. Prepared according to Example 9 from 21.4 g (0.0835 mol) of (2-furoyl-2 ') - 2 indan-2-carboxylic acid, 14.2 g (0.0835 mol 4- 20%) potassium carbonate and 14.4 g (0.0835 mol) of chloroethyldiethylamine hydrochloride. By distillation, an Ebo fraction, 5-0.4 torr * 200-220 ° C., is collected.
Spectre infrarouge: Infrared spectrum:
vCO:1740 cm-1vCO:1650 cm"1. vCO: 1740 cm-1vCO: 1650 cm "1.
Spectre RMN: NMR spectrum:
— massif de 3 protons aromatiques vers 7,83 ppm; - range of 3 aromatic protons around 7.83 ppm;
— massif de 2 protons aromatiques vers 7,3 ppm; - massif of 2 aromatic protons around 7.3 ppm;
— 1 proton aromatique vers 6,53 ppm; - 1 aromatic proton around 6.53 ppm;
— massif de 2 protons CH2 vers 4,1 ppm; - mass of 2 CH2 protons around 4.1 ppm;
— pic de 5 protons indane à 3,33 ppm; - peak of 5 indane protons at 3.33 ppm;
55 —• massif de 6 protons CH2 vers 2,7 ppm; 55 - • massif of 6 CH2 protons around 2.7 ppm;
— massif de 6 protons CH3 vers 1,07 ppm. - solid mass of 6 CH3 protons around 1.07 ppm.
Passage au chlorhydrate: Switching to hydrochloride:
60 C21H26ClNO+. 60 C21H26ClNO +.
Après recristallisation dans un mélange acétate d'éthyle/éthanol, on obtient un solide fondant à 165-166,5°C (tube capillaire). After recrystallization from an ethyl acetate / ethanol mixture, a solid melting at 165-166.5 ° C. is obtained (capillary tube).
Indice d'acidité: Acidity index:
Calculé: 142. Trouvé: 143. Calculated: 142. Found: 143.
65 65
Analyse centésimale (chlorhydrate) : Centesimal analysis (hydrochloride):
Calculé: C 64,36 H 6,69 Cl 9,05 N3,57% Calculated: C 64.36 H 6.69 Cl 9.05 N3.57%
Trouvé: C 64,44 H 6,49 Cl 8,98 N3,53% Found: C 64.44 H 6.49 Cl 8.98 N3.53%
627728 627728
Exemple 11: Example 11:
Benzoyl-5 N(N',N' diéthylamino-2' éthyl) indane-2 carboxamide: Benzoyl-5 N (N ', N' diethylamino-2 'ethyl) indan-2 carboxamide:
P.M. = 364,47 M.P. = 364.47
c2h5 c2h5
o-nh-ch2-ch2-n o-nh-ch2-ch2-n
c?.h5 c? .h5
Dans un réacteur de 250 ml équipé d'une agitation, d'un réfrigérant d'une ampoule à brome et d'un thermomètre, on introduit 25,5 g (0,2 mol + 10%) de (N'N' diéthylamino)-2 éthylamine dans 50 ml de dioxanne. A une température comprise entre 10 et 20°C, on additionne une solution de 30,2 g (0,1 mol) de chlorure d'acide benzoyl-5 indane-2 carboxylique dans 50 ml de dioxanne. On laisse ensuite revenir à température ambiante puis tourner 1 h à cette température. On concentre le dioxanne sous vide, reprend par de l'eau glacée et extrait à l'éther en milieu alcalin. L'extrait éthéré est séché sur sulfate, filtré et le filtrat concentré. On obtient une huile sur laquelle on fait un Oxalate. Après recristallisation dans un mélange acétone/alcool, on obtient un point de fusion de 153-154°C (tube capillaire). 25.5 g (0.2 mol + 10%) of (N'N 'diethylamino) are introduced into a 250 ml reactor equipped with stirring, a condenser with a dropping funnel and a thermometer ) -2 ethylamine in 50 ml of dioxane. At a temperature between 10 and 20 ° C., a solution of 30.2 g (0.1 mol) of 5-benzoyl-indan-2-carboxylic acid chloride in 50 ml of dioxane is added. It is then left to return to ambient temperature and then run for 1 hour at this temperature. The dioxane is concentrated in vacuo, taken up in ice water and extracted with ether in an alkaline medium. The ether extract is dried over sulfate, filtered and the filtrate concentrated. An oil is obtained on which an Oxalate is made. After recrystallization from an acetone / alcohol mixture, a melting point of 153-154 ° C. is obtained (capillary tube).
Indice d'acidité: Acidity index:
Calculé: 246. Trouvé: 226. Calculated: 246. Found: 226.
Spectre infrarouge: Infrared spectrum:
vCO:1660 cm-1. vCO: 1660 cm-1.
Analyse centésimale pour C25H30N2O6: Centesimal analysis for C25H30N2O6:
Calculé: Trouvé: Calculated: Found:
C 66,07 C 66,10 C 66.07 C 66.10
H 6,65 H 6,50 H 6.65 H 6.50
N 6,17% N 6,18% N 6.17% N 6.18%
Exemple 12: Example 12:
(Thénoyl-2')-5 N(N',N' diéthylamino-2' éthyl)indane-2 carboxamide: (2'-Thénoyl ') - 5 N (N', N '2-diethylamino-ethyl) indane-2 carboxamide:
\s co \ s co
C21H26N202 C21H26N202
P.M. = 370,51 M.P. = 370.51
Préparé selon l'exemple 11 à partir de 9,4 g (0,03 mol) de chlorure d'acide (thénoyl-2')-5 indane-2 carboxylique, 7,7 g (0,066 mol) de (N',N' diéthylamino)-2 éthylamine, 120 ml de dioxanne. Par passage à l'oxalate, on obtient, après recristallisation dans l'acétone, un solide fondant à 110,5-112°C (tube capillaire). 40 Prepared according to Example 11 from 9.4 g (0.03 mol) of 2-thénoyl-2-indan-2-carboxylic acid chloride, 7.7 g (0.066 mol) of (N ', N 'diethylamino) -2 ethylamine, 120 ml of dioxane. By passing to the oxalate, a solid melting at 110.5-112 ° C. is obtained after recrystallization from acetone (capillary tube). 40
Indice d'acidité: Acidity index:
Calculé: 243. Trouvé: 247. Calculated: 243. Found: 247.
co-nh-ch2-n^ co-nh-ch2-n ^
-c2h5 -c2h5
c2h5 c2h5
Spectre RMN: NMR spectrum:
— massif de 6 protons aromatiques vers 7,4 ppm; - range of 6 aromatic protons around 7.4 ppm;
— massif de 5 protons indane + 8 protons CH2 vers 3,33 ppm; - mass of 5 indane protons + 8 CH2 protons around 3.33 ppm;
— triplet de 6 protons CH3 vers 1,27 ppm. - triplet of 6 CH3 protons around 1.27 ppm.
Analyse centésimale pour C23H28N206S: Centesimal analysis for C23H28N206S:
Calculé: C 59,98 H 6,13 N6,09 S 6,96% Calculated: C 59.98 H 6.13 N 6.09 S 6.96%
Trouvé: C 59,95 H 6,26 N 5,96 S 7,06% Found: C 59.95 H 6.26 N 5.96 S 7.06%
Spectre infrarouge: vCO: 1630 cm-1. Infrared spectrum: vCO: 1630 cm-1.
45 45
Exemple 13: Example 13:
(Dichloro-2',5')-5 N(N',N' diéthylamino-2' éthyl) indane-2 carboxamide: (Dichloro-2 ', 5') - 5 N (N ', N' diethylamino-2 'ethyl) indan-2 carboxamide:
Cl co Cl co
C23H26C12N202 P.M. = 433,38 C23H26C12N202 P.M. = 433.38
Préparé selon l'exemple 11 à partir de 17,6 g (0,048 mol) de chlorure d'acide (dichloro-2',-5') benzoyl-5 indane-2 carboxylique, 13,9 g (0,12 mol) de (N'N' diéthylamino)-2 éthylamine, 80 ml de dioxanne. Par passage à l'oxalate et après recristallisation dans l'acétone, on obtient un solide fondant à 103-104°C (tube capillaire). Prepared according to Example 11 from 17.6 g (0.048 mol) of 2-dichloro-acid chloride, - 5 ') 5-benzoyl-indane-2-carboxylic acid, 13.9 g (0.12 mol) of (N'N 'diethylamino) -2 ethylamine, 80 ml of dioxane. By passage through the oxalate and after recrystallization from acetone, a solid melting at 103-104 ° C. is obtained (capillary tube).
Indice d'acidité: Acidity index:
Calculé: 216. Trouvé: 206. Calculated: 216. Found: 206.
Spectre infrarouge: Infrared spectrum:
vCO:1670 cm-1. vCO: 1670 cm-1.
c0-nk-ch2-ch2-n c2h5 c0-nk-ch2-ch2-n c2h5
c2h5 c2h5
Spectre RMN: NMR spectrum:
— massif de 6 protons aromatiques centré vers 7,46 ppm; 60 — massif de 5 protons indane 4- 8 protons CH2 vers 3,43 ppm; - range of 6 aromatic protons centered around 7.46 ppm; 60 - mass of 5 indane protons 4-8 CH2 protons around 3.43 ppm;
— triplet de 6 protons CH3 vers 1,33 ppm; - triplet of 6 CH3 protons around 1.33 ppm;
— 1 proton NH vers 8,3 ppm. - 1 NH proton around 8.3 ppm.
6J Analyse centésimale pour C25H28C12N206: 6J Centesimal analysis for C25H28C12N206:
Calculé: C 57,37 H 5,39 N5,35 Cl 13,55% Trouvé: C 57,38 H 5,48 N5,39 Cl 13,56% Calculated: C 57.37 H 5.39 N5.35 Cl 13.55% Found: C 57.38 H 5.48 N5.39 Cl 13.56%
R R
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR7637574A FR2374032A2 (en) | 1976-12-14 | 1976-12-14 | NEW CARBOXYLIC ACIDS DERIVED FROM INDANE |
Publications (1)
Publication Number | Publication Date |
---|---|
CH627728A5 true CH627728A5 (en) | 1982-01-29 |
Family
ID=9181028
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CH1541077A CH627728A5 (en) | 1976-12-14 | 1977-12-14 | Preparation of carboxylic acids derived from indane |
Country Status (21)
Country | Link |
---|---|
JP (1) | JPS5373548A (en) |
AT (1) | AT355559B (en) |
AU (1) | AU515268B2 (en) |
BE (1) | BE861826R (en) |
CA (1) | CA1088554A (en) |
CH (1) | CH627728A5 (en) |
DD (1) | DD133323A6 (en) |
DE (1) | DE2753315A1 (en) |
DK (1) | DK144640C (en) |
ES (1) | ES465056A2 (en) |
FR (1) | FR2374032A2 (en) |
GB (1) | GB1584298A (en) |
HU (1) | HU177226B (en) |
IE (1) | IE46013B1 (en) |
IL (2) | IL60599A0 (en) |
MX (1) | MX4954E (en) |
NL (1) | NL7713876A (en) |
NO (1) | NO774285L (en) |
SE (1) | SE436740B (en) |
SU (1) | SU799646A3 (en) |
ZA (1) | ZA777438B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2801182A1 (en) * | 2010-06-16 | 2011-12-22 | Metabolex, Inc. | Gpr120 receptor agonists and uses thereof |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4980053A (en) * | 1972-12-05 | 1974-08-02 | ||
JPS5838416B2 (en) * | 1974-05-31 | 1983-08-23 | 武田薬品工業株式会社 | Kanjiyoukagobutsunoseizouhou |
JPS5335944B2 (en) * | 1974-05-21 | 1978-09-29 |
-
1976
- 1976-12-14 FR FR7637574A patent/FR2374032A2/en active Granted
-
1977
- 1977-11-30 DE DE19772753315 patent/DE2753315A1/en not_active Ceased
- 1977-12-12 GB GB51699/77A patent/GB1584298A/en not_active Expired
- 1977-12-13 SE SE7714110A patent/SE436740B/en unknown
- 1977-12-13 MX MX776686U patent/MX4954E/en unknown
- 1977-12-13 DD DD7700202588A patent/DD133323A6/en unknown
- 1977-12-13 DK DK554677A patent/DK144640C/en not_active IP Right Cessation
- 1977-12-13 NO NO774285A patent/NO774285L/en unknown
- 1977-12-13 IE IE2520/77A patent/IE46013B1/en unknown
- 1977-12-13 HU HU77LI316A patent/HU177226B/en unknown
- 1977-12-14 AT AT892577A patent/AT355559B/en not_active IP Right Cessation
- 1977-12-14 ZA ZA00777438A patent/ZA777438B/en unknown
- 1977-12-14 CH CH1541077A patent/CH627728A5/en not_active IP Right Cessation
- 1977-12-14 ES ES465056A patent/ES465056A2/en not_active Expired
- 1977-12-14 BE BE183429A patent/BE861826R/en not_active IP Right Cessation
- 1977-12-14 AU AU31530/77A patent/AU515268B2/en not_active Expired
- 1977-12-14 CA CA293,076A patent/CA1088554A/en not_active Expired
- 1977-12-14 JP JP14943377A patent/JPS5373548A/en active Pending
- 1977-12-14 NL NL7713876A patent/NL7713876A/en not_active Application Discontinuation
-
1979
- 1979-04-06 SU SU792746906A patent/SU799646A3/en active
-
1980
- 1980-07-15 IL IL60599A patent/IL60599A0/en unknown
- 1980-07-15 IL IL60598A patent/IL60598A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
DE2753315A1 (en) | 1978-06-15 |
DK554677A (en) | 1978-06-15 |
NO774285L (en) | 1978-06-15 |
AT355559B (en) | 1980-03-10 |
FR2374032A2 (en) | 1978-07-13 |
IL60598A0 (en) | 1980-09-16 |
MX4954E (en) | 1983-01-13 |
GB1584298A (en) | 1981-02-11 |
DD133323A6 (en) | 1978-12-27 |
BE861826R (en) | 1978-06-14 |
DK144640B (en) | 1982-04-26 |
IL60599A0 (en) | 1980-09-16 |
ZA777438B (en) | 1979-05-30 |
DK144640C (en) | 1982-10-04 |
JPS5373548A (en) | 1978-06-30 |
SE7714110L (en) | 1978-06-15 |
CA1088554A (en) | 1980-10-28 |
IE46013L (en) | 1978-06-14 |
SE436740B (en) | 1985-01-21 |
AU515268B2 (en) | 1981-03-26 |
SU799646A3 (en) | 1981-01-23 |
AU3153077A (en) | 1979-06-21 |
IE46013B1 (en) | 1983-01-26 |
NL7713876A (en) | 1978-06-16 |
HU177226B (en) | 1981-08-28 |
ATA892577A (en) | 1979-08-15 |
ES465056A2 (en) | 1979-01-16 |
FR2374032B2 (en) | 1979-03-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0001534A1 (en) | Pyrrole derivatives, method for their preparation and their therapeutical use | |
KR960007602B1 (en) | Phenoxyalkylcarboxylic acid derivatives and the preparation process | |
CH641798A5 (en) | DIBENZOTHIEPINE DERIVATIVES AND THEIR SYNTHESIS PROCESS. | |
EP0239436B1 (en) | Tricyclic derivative, namely 5-(3-chloro-6-methyl-5,5-dioxo-6,11-dihydro-dibenzo[C,F] [1,2]-thiazepin-11-ylamino)-pentanoic acid, process for its preparation and medicines and medicines containing it | |
US3257420A (en) | Carboxylic acids alpha-substituted by at least one cyclic radical | |
FR2534582A1 (en) | NOVEL BENZOFURAN AND BENZOTHIOPHENE DERIVATIVES, USEFUL AS ANTI-HYPERURICEMIA AND ANTI-HYPERTENSION AGENTS, AND PROCESS FOR THEIR MANUFACTURE | |
CA1139763A (en) | Process for preparing novel aryltrifluoroethanols | |
CH631157A5 (en) | BENZOIC ACID DERIVATIVES, THEIR PREPARATION PROCESS AND THEIR THERAPEUTIC APPLICATION. | |
FR2637596A1 (en) | METHYL-4 ((ARYL-4-PIPERAZINYL-1) -2-ETHYL) -5 THIAZOLE AND ITS DERIVATIVES, PROCESS FOR PREPARING THEM AND MEDICAMENTS CONTAINING THE SAME | |
EP0064445A1 (en) | N-substituted 2,4-dialkoxybenzene sulfon amides | |
FR2600647A1 (en) | GLYCINE DERIVATIVES | |
CH627728A5 (en) | Preparation of carboxylic acids derived from indane | |
CH628014A5 (en) | Gamma-aryl-gamma-oxoisovaleric acids having antiphlogistic and antalgic properties | |
CH617173A5 (en) | ||
CA1249834A (en) | Process for preparing 5,6-dihydro-4h-cyclopenta ¬b|thiophene-6-carboxylic acids | |
US3646066A (en) | Adamantylamino-tetrahydronaphthyl-oxypropanols and ester derivatives | |
FR2560873A1 (en) | PIPERIDINE DERIVATIVE MEDICINES, NOVEL PIPERIDINE DERIVATIVES AND METHODS FOR PREPARING THE SAME | |
EP0100257B1 (en) | Aminoalkyl naphthalene derivatives, their salts, process for their preparation and the therapeutical use of these derivatives and salts | |
CH648299A5 (en) | N (1 ALLYL 2 PYRROLIDINYL METHYL) 2 METHOXY 4 AMINO 5 METHYLSULFAMOYL BENZAMIDE. | |
LU86706A1 (en) | NOVEL BENZO (4,5) CYCLOHEPTA (1,2-B) THIOPHENE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | |
US4795758A (en) | 5-[2-(pyrrolidin-1-yl)ethoxy]-p-cymene derivatives, the process for the preparation of the said derivatives and drugs in which the said derivatives are present | |
FR2649981A1 (en) | DIHYDROPYRIMIDOTHIAZINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | |
EP0288647B1 (en) | Derivatives of 5-[2-(1-pyrrolidinyl)ethoxy]-p-cymene, process for their preparation, and medicaments containing these derivatives | |
FR2547726A1 (en) | 2- (4-BIPHENYL) -4-HEXENOIC ACID AND DERIVATIVES HAVING ANTI-INFLAMMATORY ACTIVITY | |
FR2581643A1 (en) | Pharmaceutical compositions useful in the field of urology, containing 1-acetoxy-2-methyl-4-[2-(piperidino)ethoxy]-5-(1-methylethyl)benzene or one of its salts |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PL | Patent ceased |